Ahmedabad-based drugmaker Lincoln Pharmaceuticals Limited has reported a 37.7% year-on-year rise in consolidated net profit for the third quarter of FY26, reflecting steady demand across key therapy segments and improved operational performance.
The company posted a net profit of Rs 28.60 crore for the quarter ended December 2025, compared with Rs 20.77 crore in the same period last year. Revenue from operations rose 13.49% to Rs 166.32 crore, up from Rs 146.55 crore in Q3 FY25.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 18.73% year-on-year to Rs 38.74 crore, while earnings per share climbed to Rs 14.28 from Rs 10.37 a year earlier.
For the first nine months of FY26, revenue from operations stood at Rs 483.75 crore, marking a 6.31% increase from the previous year. Net profit during the period rose 7.76% to Rs 76.26 crore, while EBITDA grew 6.10% to Rs 110.48 crore.
The company said it is targeting revenue of Rs 1,000 crore over the next three years, supported by expansion into high-value product categories and entry into new markets. It aims to deliver annual growth of 15–18%, driven by strong performance in cardiac, diabetic, dermatology and ENT segments.
Earlier this year, CRISIL Ratings reaffirmed its ‘CRISIL A/Stable/CRISIL A1’ ratings on the company’s bank facilities. The agency cited the promoters’ industry experience, established market position and healthy financial profile, while noting ongoing working-capital intensity and regulatory and competitive risks.
Foreign institutional investors held a 4.70% stake in the company as of 31 December 2025. Lincoln Pharmaceuticals said it remains focused on strengthening its domestic presence while expanding its global footprint.
